DeepView Wound Imaging System
Diabetic Foot Ulcers (DFU)
Key Facts
About Spectral AI
Spectral AI is a Dallas-based medical technology company founded in 2019, focused on transforming wound care through AI-driven predictive analytics. Its DeepView System uses multispectral imaging and machine learning to generate a binary healing prediction for wounds like diabetic foot ulcers on day one of assessment, aiming to improve clinical outcomes and reduce costs. The technology is currently investigational, backed by a substantial intellectual property portfolio of 26 patents, and is positioned to address a significant unmet need in chronic wound management.
View full company profileAbout Spectral AI
Spectral AI is a Dallas-based medical technology company founded in 2019, focused on transforming wound care through AI-driven predictive analytics. Its DeepView System uses multispectral imaging and machine learning to generate a binary healing prediction for wounds like diabetic foot ulcers on day one of assessment, aiming to improve clinical outcomes and reduce costs. The technology is currently investigational, backed by a substantial intellectual property portfolio of 26 patents, and is positioned to address a significant unmet need in chronic wound management.
View full company profileTherapeutic Areas
Other Diabetic Foot Ulcers (DFU) Drugs
| Drug | Company | Phase |
|---|---|---|
| Intralesional rhEGF (Heberprot-P related) | Discovery Therapeutics Caribe | Phase 3 |
| Nanordica® Advanced Antibacterial Wound Dressing | Nanordica Medical | Phase 2/3 |
| ORBCEL™ for Diabetic Foot Ulcers | Orbsen Therapeutics | Pre-clinical/Research |
| ABCB5+ MSCs | RHEACELL | Pre-clinical development |